Trial Profile
Dynamics of Th17 cells during and after cessation of natalizumab therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- 26 Feb 2016 New trial record